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The  pharmacokinetics  of afoxolaner  in dogs  was  evaluated  following  either  intravenous  or
after  oral  administration  of  NEXGARD®, a soft  chewable  formulation.  Afoxolaner  is a mem-
ber of  one  of the  newest  classes  of antiparasitic  agents,  known  as  antiparasitic  isoxazolines.
The soft  chewable  formulation  underwent  rapid  dissolution,  and  afoxolaner  was  absorbed
quickly  following  oral  administration  of  the  minimum  effective  dose  of  2.5  mg/kg,  with
maximum  plasma  concentrations  (Cmax)  of  1655  ± 332  ng/mL  observed  2–6 h  (Tmax)  after
treatment.  The  terminal  plasma  half-life  was  15.5  ±  7.8  days,  and  oral  bioavailability  was
73.9%.  Plasma  concentration-versus-time  curves  ﬁt a  2-compartment  model  and  increased
proportionally  with  dose  over  the  oral  dose  range  of  1.0–4.0  mg/kg,  and  over  the oral  dose
range from  1.0 to 40  mg/kg.  Following  an intravenous  dose  of  1  mg/kg,  the  volume  of  dis-
tribution  (Vd)  was  2.68  ±  0.55  L/kg,  and the  systemic  clearance  was  4.95  ± 1.20  mL/h/kg.
Afoxolaner  plasma  protein  binding  was  >99.9%  in dogs.  One  major  metabolite,  formed  fol-
lowing  hydroxylation  of  afoxolaner,  was  identiﬁed  in dog  plasma,  urine  and  bile.  When
afoxolaner  is administered  orally,  there  is a strong  correlation  between  afoxolaner  plasma
concentration  and  efﬁcacy  with  EC90 values  of 23 ng/mL  for  Ctenocephalides  felis  and
≥100  ng/mL  for  Rhipicephalus  sanguineus  sensu  lato  and  Dermacentor  variabilis.  The pharma-
cokinetic  properties  of afoxolaner  are  suited  for  a monthly  administration  product  because
the fast absorption  and  long  terminal  half-life  support  a  rapid  onset  of action  while  ensuring
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1. Introduction
Afoxolaner is a member of one of the newest classes
of antiparasitic agents known as antiparasitic isoxazo-
lines (Fig. 1). Originally evaluated for use in crops, the
isoxazolines are highly effective against ﬂea and tick infes-
tations in dogs (Ozoe et al., 2010; Woods et al., 2011). The
antiparasitic mode of action is mediated primarily through
interaction with the arthropod GABA receptor. Activity at
the glutamate-gated chloride channel receptors also has
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licenses/by-nc-nd/3.0/).lished  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
been implicated (Garcia-Reynaga et al., 2013), with both
channels functioning at the central nervous system and/or
neuromuscular junction resulting in irreversible hyperex-
citation in the targeted arthropods (Shoop et al., 2014).
The speciﬁcity of a drug to insect and acari neuroreceptors,
rather than mammalian neuroreceptors, is predictive of the
margins of safety for the antiparasitic drug (Gupta, 2012;
Ensley, 2012). As with the isoxazoline A1443 which is 2000-
fold more potent for houseﬂy GABA receptors than for those
found in rat brain membranes (Ozoe et al., 2010), radioli-
gand binding assays show that afoxolaner, at the doses used
in dogs, does not bind to mammalian GABA or glutamate
receptors (Chen and Lin, 2010). To support these in vitro
results, the lack of effect on the mammalian nervous system
ss article under the CC BY-NC-ND license (http://creativecommons.org/
L. Letendre et al. / Veterinary Parasit
HN
O
HN
F3C
O
F3C
Cl
F3C
a
o
S
a
a
i
i
e
F
s
t
(
a
o
l
t
m
s
p
a
t
t
d
a
b
2
2
u
1
w
p
c
2
w
u
2
ﬁ
d
a
a
t
r
CO
N
Fig. 1. Molecular structure of afoxolaner.
t clinically relevant doses was conﬁrmed in numerous lab-
ratory and target animal safety studies (Drag et al., 2014;
hoop et al., 2014).
Given both speciﬁcity and potency on the targeted par-
site, the success of a systemically active antiparasitic
gent largely depends on the pharmacokinetic properties
n the targeted species. The speed and duration of action
s driven by the absorption, distribution, metabolism and
xcretion of the antiparasitic agent in vivo (Beugnet and
ranc, 2012). Two marketed active ingredients demon-
trate this principle. Nitenpyram is a fast-acting oral ﬂea
reatment with a short oral plasma half-life of 2 h in dogs
Maddison et al., 2008), which makes the duration of its
ction too short for convenient and compliant use as an
ral monthly product. Spinosad, on the other hand, has a
ong plasma half-life of 7–10 days (Holmstrom et al., 2012)
herefore preventing and treating ﬂea infestations for one
onth. In contrast to the currently available oral antipara-
itic agents for dogs, the ideal pharmacokinetic and efﬁcacy
roﬁle would demonstrate both a rapid onset of action
nd monthly duration of efﬁcacy against ﬂeas and multiple
ick species. These attributes are achieved with an easy-
o-administer oral soft chewable formulation for dogs, as
emonstrated by the afoxolaner pharmacokinetic proﬁle
nd PK/PD correlation discussed herein and supported by
oth efﬁcacy and safety data.
. Materials and methods
.1. Protein binding
Protein binding was determined via equilibrium dialysis
sing a Dianorm Multi-Equilibrium DIALYZER at 200, 500,
000, 2000 and 10,000 ng/mL of afoxolaner in dog plasma
ith buffer and plasma chambers separated by a semi-
ermeable cellulose membrane with a molecular weight
utoff of 10,000 Dalton. Incubations were performed for
.5 h (37 ◦C), after which the afoxolaner concentrations
ere measured in the buffer and plasma compartments
sing LC–MS analysis (see below).
.2. In vivo pharmacokinetic studies
For all in vivo studies, animals were treated with the
nal formulation of afoxolaner except when noted. All
ogs were purpose-bred, ≥6 months of age, and weighed
pproximately 5–19 kg. The number of dogs in each study
nd other study details are described in Table 1 and in the
ext below. All animal procedures in these studies were
eviewed and approved by Merial Institutional Animal
are and Use Committee (IACUC) and dogs were handledology 201 (2014) 190–197 191
with due regard for their welfare (USDA, 2008, 9 CFR).
Blood samples were taken prior to treatment, and peri-
odically until the end of each study. All blood samples
were processed into plasma and stored frozen until ana-
lyzed. Afoxolaner plasma concentrations were determined
using a validated LC–MS method (Nguyen, unpublished
data) and pharmacokinetic analysis via noncompartmental
and/or compartmental analysis was  performed. All study
times are relative to Day 0, the day of dosing. Six pharma-
cokinetic studies were performed. The purpose and study
design details are given in Table 1. Some details of PK Study
6 and two efﬁcacy studies are given below.
2.3. Route of elimination studies
Six male Beagles were studied to determine the renal
and biliary clearance of afoxolaner when administered as
a soft chewable formulation once, orally, at 30–45 mg/kg
(PK Study 6). Four of the dogs underwent bile duct cannula-
tion prior to study start to allow bile collection throughout
the study. Hematology and serum chemistry samples from
all dogs were evaluated prior to treatment to assure nor-
mal  liver functioning. Dogs were fasted prior to treatment.
Plasma, urine and bile samples were collected and stored
frozen (−20 ◦C) until analysis. Bile and urine were col-
lected from the cannulated dogs over 3-h intervals for the
ﬁrst 12 h and then over 12 h intervals until 72 h post-dose.
Blood was collected at time points between the bile and
urine collection periods (e.g. at 1.5 h, the midpoint of the
0–3 h collection period). Afoxolaner urine and bile concen-
trations were determined quantitatively using an LC–MS
method (Wenkui et al., 2013). Additionally, plasma, urine
and bile samples were scanned for metabolites of afox-
olaner. Biliary and renal clearances were calculated for
each dosing interval (Rowland and Tozer, 1995) as in the
following: biliary clearance = bile ﬂow × concentration in
bile/concentration in plasma and urinary clearance = urine
ﬂow × concentration in urine/concentration in plasma. The
dosing intervals for each animal were averaged for each
matrix. The bile and urine ﬂow parameter for dogs were
based on the data published by Davies and Morris (1993).
To estimate the percentage of the total clearance attributed
to biliary and renal clearance, the average total clearance
(5.0 ± 1.2 mL/h/kg) from the IV Treatment Group in PK
Study 2 was used.
Metabolite identiﬁcation was performed on plasma
samples taken 4 h and 1, 2, 4 and 6 days after administra-
tion of 25 and 100 mg/kg given orally as a solution in dog
studies.
2.4. Preliminary efﬁcacy studies
Sixteen male and female Beagle dogs (4 dogs/group; 3
oral dose groups/study and 1 control group/study) were
studied to determine the effectiveness of afoxolaner when
administered once as an oral soft chewable to dogs against
induced infestations with 50 D. variabilis ticks and 100 C.
felis ﬂeas (Study 1) and 50 R. sanguineus sensu lato and
100 C. felis (Study 2). For each study, Treatment Group 1
included 4 untreated control dogs and Treatment Groups
2, 3 and 4 were treated with soft chewable formulations
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Table 1
Study design details for pharmacokinetic studies.
Study name PK Study 1 PK Study 2 PK Study 3 PK Study 4 PK Study 5 PK Study 6
Purpose PK proﬁle; dose
proportionality
assessment
PK proﬁle; oral
bioavailability
Multiple dose
kinetics
Assess the effect
of prandial state
Assess dose
proportionality
at high doses
Determine the
route of
elimination
Prandial statea Fasted Fasted Fasted 1: Fed 2: Fasted Fed Fed
Breed  Mongrel Beagle Beagle Beagle Beagle Beagle
Type  GLP GLP GLP GSP GSP GSP
Dogs/group 8 6 6 5 5 6
Group:  dose level 1: 1.0 mg/kg
2: 2.5 mg/kg
3: 4.0 mg/kg
1: 1.0 mg/kg
2: 2.5 mg/kg
1: 2.5 mg/kg 1: 2.5 mg/kg
2: 2.5 mg/kg
1: 20 mg/kg
2: 40 mg/kg
30–45 mg/kg
Treatment day 0 0 0, 28 and 56 0 0 0
Route  of administration Oral 1: IV
2: Oral
Oral gavage Oral Oral Oral
Group:  treatment All groups:
Nexgard®
1: IV solutionb
2: Nexgard®
1: Solutionb 1: Soft chewc 1: Soft chewc 1: Soft chewc
Blood sampling timesd Day 0: 2, 4, 6,
10 h
Days 1, 7, 14, 21,
28, 35, 41, 48, 55
(Day 0: 15,
30 min  IV Group
only)
Day 0: 1, 2, 4, 8,
12 h
Days: 1, 3, 7, 18,
35, 42, 72
Day 0: 2, 4, 8
Day 1, 3, 7, 14,
21, 28 relative to
each of the 3
doses
Day 0: 2, 4, 6, 8,
10 h
Days 1, 2, 9, 16,
23, 30
Day 0: 4, 12 h
Days 1, 2, 7, 14,
21, 30, 44, 58, 72,
80, 86 and 93
(Day 105 Group 1
only).
1.5, 4.5, 6, 8.5,
10.5, 12, 18, 30,
42, 54, 66, 72 h
after treatment
GLP, good laboratory practices; GSP, good scientiﬁc practices. Validated bioanalytical methods were used for all studies.
a Fasted: food was removed the night before treatment and withheld until 4 h after treatment.
 Nexgar
bile collb Afoxolaner was  formulated in a 8:2 (v/v) solution of PEG400:Ethanol.
c Chewable formulations contained afoxolaner and were similar to the
d Pretreatment samples taken for all groups. For PK Study 6, urine and 
administered orally at approximately 1.5, 2.5 and 3.5 mg/kg
body weight, respectively. All dogs were infested with
100 ± 5 adult C. felis and 50 ± 5 adult D. variabilis or R. sang-
uineus sensu lato. Study 1 dogs were infested with C. felis
on days −1, 8, 15, 22, 29, 35, 43 and 57. Study 1 dogs were
infested with D. variabilis on days −1, 7, 14, 21, 28, 34 and
42. Study 2 dogs were infested with C. felis on days −1, 8,
15, 22, 29, 36, and 43. Study 2 dogs were also infested with
R. sanguineus sensu lato on days −1, 7, 14, 21, 28, 35 and
42. All ticks and ﬂeas were counted upon removal on Days
2, 9, 16, 23, 30, 37 and 44 for both studies, they were then
categorized as live or dead (and for ticks also attached or
free). Additionally, ﬂeas were counted on Day 58 in Study
1. Blood samples were collected prior to treatment, on Day
0 at 4 and 12 h and on Days 1, 2, 9, 16, 23, 30, 36 (Day 37 for
Study 2), and 44 in Study 1 and 2 and additionally on Days
51, 58, 64, 72, 79, 86 in Study 1. The later sampling times in
study 2 were taken to determine the full pharmacokinetic
proﬁle of afoxolaner in dogs.
2.5. LC–MS analysis
Plasma samples from all studies were analyzed quan-
titatively to determine compound concentrations using
a method based on 96-well solid phase extraction of
afoxolaner from canine plasma and a proprietary internal
standard. The extracted analytes were chromatographed
by reverse-phase HPLC and quantiﬁed by a Waters
Micromass® Quattro Ultima®, Waters Micromass® Micro
or Sciex Qtrap® 3200 triple quadrupole mass spectrometer
system using the electrospray interface. Drug and internal
standard were detected in positive ionization mode using
multiple reaction monitoring (MRM)  of the precursor tod® formulation.
ection intervals are discussed in the text.
product ions transition of m/z 626→470. Repeatability
(precision), accuracy, assay speciﬁcity, stability in plasma,
and all solutions and method robustness were veriﬁed and
passed FDA guidelines for validated bioanalytical meth-
ods (http://www.fda.gov/downloads/Drugs/Guidances/
ucm070107.pdf). The validated lower limits of quantita-
tion were 5 ng/mL (lower) and 500 ng/mL (upper), based
on calibration curves that ranged from 5 to 500 ng/mL
afoxolaner in 0.250 mL  plasma. The limit of detection was
1.0 ng/mL. Dilution quality control samples also passed all
guideline criteria, and afoxolaner plasma concentrations
above 500 ng/mL were diluted in plasma prior to sample
extraction.
2.6. Metabolite identiﬁcation
Selected dog plasma samples were scanned using
LC–MS techniques for metabolites of afoxolaner. The
plasma samples from control and treated dogs were pre-
pared via solid phase extraction and protein precipitation.
Structural elucidation was accomplished using accurate
mass measurements and molecular formulae determi-
nations. The molecular ion peak of the metabolite was
conﬁrmed by its characteristic 35Cl/37Cl isotope peak clus-
ters representing each mass peak due to the natural relative
abundance of each chlorine isotope in the mass spectrum.
Elemental composition was determined by MassLynx® 4.1
software based on the accurate mass measurement using
a Waters QTof mass spectrometer. The site of hydroxyl-
ation was determined based on the daughter ion, which
was  a result of loss of CF3CHO group from the hydroxyla-
ted metabolite. HPLC-photodiode array (PDA) and total ion
chromatograms were determined also. The UV (312 nm)
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eak areas of both afoxolaner and the metabolite, for each
nimal and at each time point, were compared to estimate
he relative percent of the metabolites formed. This gave a
ood estimate because the UV response (absorption max-
ma) for afoxolaner and the metabolites are approximately
he same.
.7. Pharmacokinetic analysis
Pharmacokinetic parameters were determined using
he WinNonlin® software (Pharsight Corp, version 5.0.1).
ll plasma concentrations from samples taken prior to the
rst dose were below the LLOQ of the method. Concentra-
ions < LLOQ were not used in PK calculations.
.8. Noncompartmental analysis
All pharmacokinetic parameters were calculated using
he individual plasma concentration data. The ﬁrst order
ate constant, z, associated with the terminal log-linear
ortion of the curve was estimated via linear regression
f the log plasma concentration versus time curve. The
erminal plasma half-life (T1/2) was calculated using the
atural logarithm (2)/z. The area under the plasma afox-
laner concentration versus time curve from the time of
osing to Tlast (AUC0-Tlast ) was calculated by a linear up
og down trapezoidal method and extrapolated to inﬁnity
sing the equation AUC0-Tlast + Clast/z. The average steady
tate plasma concentration was calculated by dividing the
UC over one dosing interval by the time of the dosing
nterval.
.9. PK/PD analysis for tick and ﬂea efﬁcacy
An Emax model (Eq. (1)) was used to describe the
elationship between plasma concentration and percent
fﬁcacy (the effect). The ﬂea or tick count taken 24 h (ﬂea)
r 48 h (tick) after infestation was compared to the ﬂea or
ick count at the same time on control dogs that were not
reated, and a percent difference from control was  calcu-
ated as follows: {1 − [count (X h post-infestation) for dog
]/[geometric mean count for the control dogs at X h post-
nfestation]} × 100, where count = the number of live ﬂeas
r ticks. The percent efﬁcacy versus afoxolaner plasma con-
entration was input into the WinNonlin® software and ﬁt
o a Sigmoid Emax model (Eq. (1)). In the model the Effect is
et to 0% when plasma concentrations are 0. The maximal
ffect, Emax, is a parameter determined by the model and
xpected to be close to 100% and is a measure of maximal
fﬁcacy. The following equation was used to ﬁt the data:
ffect(t) = Emax × C(t)
Gamma
C(t)Gamma + EC50Gamma
Emax Model (1)
EC50 is the plasma concentration corresponding to
max/2 and is a measure of potency. C(t) is the measured
foxolaner plasma concentration at time t, and Gamma, a
easure of the selectivity, is related to the steepness of the
lasma concentration versus effect curve. The Nedler Mead
lgorithm was used without weighting to estimate the
arameters of the model. The EC90, the afoxolaner plasmaology 201 (2014) 190–197 193
concentration estimated to provide 90% efﬁcacy, was then
calculated using the following equation:
EC90 = EC50 ∗
(
90
100 − 90
)1/Gamma
2.10. Dose proportionality
Dose proportionality was  assessed by calculating the
strength of a linear relationship between AUC and dose or
between Cmax and dose using the power method (Hummel
et al., 2009). Log dose versus log AUC0-Tlast , AUC0-Inf or
Cmax were ﬁt using linear regression with reciprocal dose
weighting. The upper and lower 95% conﬁdence and predic-
tion intervals also were determined, and the residuals were
tested for normality. The parameters (AUC0-Tlast , AUC0-Inf or
Cmax) were considered to increase proportionally with dose
if the slope of the Log dose versus Log parameter curve was
completely within the 95% conﬁdence interval of 0.8–1.25.
2.11. Linear pharmacokinetics
To conﬁrm that the pharmacokinetic processes were
linear, afoxolaner plasma concentration versus time curves
for each dog following multiple monthly dosing were
simulated using parameters from the single dose two-
compartment analysis and assuming linear kinetics.
3. Results
3.1. Protein binding
The extent of plasma protein binding was greater
than 99.9% in dog plasma over the range of afoxolaner
plasma concentrations tested (200–10,000 ng/mL). Afox-
olaner, therefore, is highly bound to plasma proteins of dog,
and protein binding is independent of concentration over
the range of 200–10,000 ng/mL.
3.2. Pharmacokinetic proﬁle of afoxolaner in dogs
Following a 1 mg/kg IV dose, the afoxolaner plasma
concentrations decreased bi-exponentially with a rapid
distribution phase and a long elimination phase. The indi-
vidual afoxolaner plasma concentration versus time curves
ﬁt well to a two compartment (bi-exponential) model (data
not reported). The Vdss was 2.68 ± 0.55 L/kg, and the sys-
temic clearance (Cl) was  4.95 ± 1.20 mL/h/kg. Afoxolaner
IV and oral PK parameters are given in Table 2.
Following oral administration of Nexgard® to dogs,
plasma concentrations peaked quickly, indicating rapid
dissolution and absorption from the soft chewable
formulation. Afoxolaner was well-absorbed with oral
bioavailability in PK Study 2 of 73.9%. After Tmax, the afox-
olaner plasma concentrations declined bi-exponentially
with a fast distribution phase occurring over the ﬁrst day
(Day 0). The oral plasma concentrations also ﬁt well to a two
compartment (bi-exponential) model (data not reported).
The terminal plasma half-life was the same following IV
and oral administration, indicating the terminal afoxolaner
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Table 2
PK Study 1 and 2; mean ± standard deviation of pharmacokinetic parameters for afoxolaner following oral administration of afoxolaner in a soft chewable
formulation or intravenous administration of a solution to Mongrel and Beagle dogs.
Parameter PK Study 1
Mongrel dogs, n = 8/group
PK Study 2
Beagle dogs, n = 6/group
Group 2 Group 3 Group 4 Group 1 (IV) Group 3
Route of administration Oral chew Oral chew Oral chew Intravenous solution Oral chew
Dose  (mg/kg) 1.0 2.5 4.0 1.0 2.5
T1/2 (day) 14.4 ± 3.6 15.2 ± 5.1 15.6 ± 9.0 15.6 ± 7.3 15.5 ± 7.8
Tmax (h) 2–6 2–4 2–6 0.25a 2–4
Cmax (ng/mL) 538 ± 85 1384 ± 330 2147 ± 575 1107 ± 190a 1655 ± 332
Tlastb (day) 55 55 55 42–72 14–72
Clast (ng/mL) 24.6 ± 13.6 72.6 ± 53.8 113 ± 90 21.9 ± 13.5 54.5 ± 31.4
AUC0-Tlast (day g/mL) 6.7 ± 1.3 17.2 ± 4.9 26.6 ± 5.6 8.18 ± 1.53 14.8 ± 8.2
AUC0-Inf (day g/mL) 7.2 ± 1.6 19.1 ± 6.7 30.1 ± 7.3 8.78 ± 2.02 16.2 ± 9.4
AUC  % Extrap 7.3 ± 4.4 8.7 ± 6.0 10.4 ± 10.3 6.0 ± 5.4 7.4 ± 3.8
t abovea First time point.
b Last measured time point for PK Study 1 and last measured time poin
plasma concentrations represent a true elimination phase.
This long terminal phase spanned from approximately Day
2 until the ﬁnal time point for each study [see e.g. Fig. 2]. In
PK Study 5, a single exponential decay accurately described
the plasma concentration curve from Day 2 to Day 105.
The pharmacokinetic proﬁle of afoxolaner following
oral administration was determined in over 145 treated
dogs and found to be predictable and comparable across
all studies in the Nexgard® development program (some
studies not reported in detail here). The pharmacokinetic
parameters from PK Studies 1 and 2 are given in Table 2. The
afoxolaner plasma concentration versus time curves on a
semilog scale for the Nexgard® treatment groups reported
in PK Study 1 are shown in Fig. 2.
A single major metabolite, hydroxylated afoxolaner,
was observed in dog plasma as an oxidation product
presumed to be formed via cytochrome P450 enzymes.
Although the metabolite identiﬁcation was performed
qualitatively, the amount of metabolite present relative to
parent afoxolaner was estimated using HPLC UV peak areas
and found to be between approximately 2.5 and 17.8%.
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Fig. 2. Mean afoxolaner plasma concentration versus time curves fol-
lowing oral administration of 1.0, 2.5 and 4.0 mg/kg of Afoxolaner in
Nexgard® chewable formulation to Mongrel dogs (n = 8/treatment group)
in  PK Study 1. the limit of quantitation for PK Study 2.
Concentrations of afoxolaner in the bile ranged from
104 to 7900 ng/mL and the biliary clearance was  on aver-
age 1.5 mL/h/kg. Afoxolaner urine concentrations were
below the limit of quantitation of the bioanalytical method
(<1.25 ng/mL), and the renal clearance of parent afoxolaner
could therefore not be determined. Urine and bile samples
also were analyzed for afoxolaner metabolites. The urine
contained a hydroxylated afoxolaner and an afoxolaner
acid metabolite. The bile samples contained the hydroxy-
lated afoxolaner metabolite and afoxolaner. The acid of
afoxolaner was not detected in the bile.
3.3. Multiple dose kinetics of afoxolaner to dogs
Following oral 2.5 mg/kg doses of a solution adminis-
tered 3 times at 28 day intervals, the maximum afoxolaner
plasma concentrations were 699 ± 315, 1150 ± 450, and
908 ± 147 ng/mL, observed approximately 3-h after the 1st,
2nd and 3rd dose, respectively. The average concentration
at steady state was approximately 260 ng/mL and was sim-
ilar after each dose.
Experimental data show low accumulation with a ratio
of AUC0-Inf (Dose #3) to AUC0-Inf (Dose #1) of approxi-
mately 1.0. The ratio for Cmax in this study was  1.3 (a 30%
increase from Dose #1 to Dose #3). The half-life was  com-
parable after each of the 3 monthly doses. The simulation
assuming linear kinetics agrees with the measured plasma
concentrations (Fig. 3). These results are consistent with
those observed by Shoop et al. (2014) following 5 monthly
doses of afoxolaner to dogs.
3.4. Impact of prandial state on afoxolaner exposure
Maximum afoxolaner plasma concentrations for the fed
dogs averaged 1366 ± 276 ng/mL, and the time to maxi-
mum concentration was  between 2 and 24 h for most dogs.
Fasted dogs had maximum afoxolaner plasma concen-
trations of 1453 ± 374 ng/mL, and the time to maximum
concentration was  2 h for all 5 dogs in this treatment group.
The overall exposure (AUCInf) was  not affected by the
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Fig. 4. Log afoxolaner Cmax [A] and AucInf [B] versus log dose following oral
administration of afoxolaner in a soft chewable formulation to Mongrel
and Beagle dogs over the range of 1–40 mg/kg from two studies: PK Studyig. 3. Experimental (diamond) and simulated (dashed line) afoxolaner
lasma concentration versus time curve following multiple 2.5 mg/kg
oses to Beagle dogs (n = 6) on Days 0, 28 and 56.
randial state of the dogs (13.0 ± 2.9 and
0.9 ± 2.6 g day/mL for fed and fasted dogs, respectively).
.5. Dose proportionality over the range of 1–40 mg/kg
Cmax, AUC0-Tlast and AUC0-Inf increased proportionally
ith dose, indicating linear pharmacokinetics over the
ange of 1.0–4.0 mg/kg when afoxolaner chews were
dministered orally in PK Study 1. Table 3 shows the param-
ters from the Power Model ﬁt for PK Study 1.
Including the Cmax and AUC0-Inf values from PK Study 5
eveals that afoxolaner exhibited close to linear kinetics for
bsorption, elimination and distribution processes (ADME)
ver the range of 1–40 mg/kg. The data were obtained from
wo different studies and therefore are not included in one
tatistical analysis; nonetheless, the log Cmax versus Dose
nd Log AUC0-Inf versus Dose graphs covering the full range
f doses tested are given in Fig. 4.
.6. Effective afoxolaner plasma concentrations
Examples of the ﬂea and tick efﬁcacy as a function of
lasma concentration are given in Fig. 5A and B, respec-
ively. A direct relationship between plasma concentration
nd percent of effectiveness relative to control dogs was
odeled using a Sigmoidal Emax model. The EC90 afox-
laner concentrations was estimated to be: 23 ng/mL (24 h
ost infestation) for C. felis and ≥100 ng/mL (48 h post infes-
ation) for R. sanguineus and D. variabilis.
. Discussion
The physicochemical properties of any drug affect its
bility to cross cell membranes and therefore govern the
bsorption, tissue distribution, and elimination of the drug
n vivo. The molecular size, solubility, degree of ioniza-
ion (indicated by pKa), and relative solubility in lipid and
queous environments (indicated by the lipid:water parti-
ion coefﬁcient, i.e., log P or log D) are therefore important
arameters for understanding pharmacokinetic behavior
Jenkins and Cone, 1998). Afoxolaner has extremely weak
cid/base properties and is essentially unionized over the1  (1, 2.5 and 4 mg/kg) and PK Study 2 (20 and 40 mg/kg). Fit using linear
regression with reciprocal dose weighting is also shown along with the
95%  conﬁdence and prediction limits.
physiological pH range (pH 1–12). This small, lipophilic,
unionized compound is therefore expected to cross cell
membranes freely via passive diffusion driven by a con-
centration gradient.
Afoxolaner pharmacokinetic properties have been
tested in a number of in vivo studies and follow the expec-
tations for a Biopharmaceutics Classiﬁcation System (BCS)
Class II compound. For BCS Class II compounds, if dis-
solution is complete and the drug is in solution, high
bioavailability is expected due to the high permeabil-
ity. High permeability compounds readily access enzymes
within the hepatocytes and therefore may  be eliminated
primarily by metabolism. These compounds also tend to
distribute into tissues (Wu  and Benet, 2005).
Afoxolaner distributes into tissues, Vd of
2.68 ± 0.55 L/kg, as expected for a lipophilic compound
(Toutain and Bousquet-Melou, 2004). The single expo-
nential decay of afoxolaner in plasma during the terminal
phase from Day 2 to 3 months suggests that no special
tissue depots are present in the dog. This conclusion
is consistent with the physical chemical properties of
afoxolaner, which favor passive diffusion into and out of
tissues. Active transport, if occurring, was not saturated
under the conditions/dose levels tested.
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Table 3
Log parameter versus log dose ﬁtted parameters, 95% conﬁdence limits and dose proportionality assessment for PK parameters for range of 1–4 mg/kg [PK
Study  1, n = 8 Mongrel dogs per treatment group].
Parameter Intercept Slope Conﬁdence limits Dose
Estimate SE Lower Upper Proportional
C 6.27812 0.99533 0.07296 0.84402 1.14663 Yes
.07604 
.08754 max
AUC0-Tlast 8.79092 1.00333 0
AUCInf 8.86672 1.02829 0
Afoxolaner has a low systemic clearance of
4.95 ± 1.20 mL/h/kg, determined following IV admin-
istration. The low clearance is much less than the hepatic
blood ﬂow in dogs (1854 mL/h/kg), as reported in Davies
and Morris (1993) and is responsible primarily for the long
half-life of afoxolaner in dogs. Clearance may  be closely
dependent on either free drug concentrations, where
signiﬁcant protein binding (>99.9% for afoxolaner) limits
the drug available for renal and hepatic elimination, or on
the intrinsic ability of hepatocytes to metabolize the drug
(Rowland and Tozer, 1995).
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Fig. 5. Mean % efﬁcacy against Dermacentor variabilis (Ticks) [A] and
Ctenocephalides felis (Fleas) [B] versus afoxolaner plasma concentration
following oral administration of afoxolaner in Nexgard® to Beagle dogs.
The line represents the ﬁt to a sigmoid Emax model. The triangles are the
experimental values. In Fig. 5B, plasma concentrations > 400 ng/mL are not
shown and efﬁcacy for those levels was 100% in all cases.0.84563 1.16103 Yes
0.84675 1.20983 Yes
Plasma, urine and bile were collected to establish the
primary route for elimination. Afoxolaner concentrations
in the bile were high, and the biliary clearance was on
average 1.5 mL/h/kg. This clearance is about 30% of the
total clearance measured in PK Study 2, with individ-
ual dogs ranging in biliary clearance from 10 to 44% of
the total clearance. Afoxolaner reabsorption was experi-
mentally hindered by the biliary collection in this study,
therefore, 30% is considered an upper limit of the total
afoxolaner biliary clearance from the body. Using the esti-
mated urine afoxolaner values that were below the limit of
quantitation (<1.25 ng/mL), renal clearance of the parent
compound was  calculated to be less than 0.01% of the total
clearance.
The afoxolaner plasma concentrations from fed and
fasted dogs are within the biological or inter-animal vari-
ability as shown by the standard deviations of the two
groups. The differences were not therapeutically relevant
or statistically signiﬁcant (  ˛ = 0.05).
As reported, the terminal plasma half-lives were
15.2 ± 5.1 and 15.5 ± 7.8 days in two studies investigating
the minimum effective dose of 2.5 mg/kg. The mean half-
life of afoxolaner administered orally at a dose of between
1 and 4 mg/kg, is 12.8 ± 5.6 days in 145 adult Beagle and
Mongrel dogs from across the multiple studies. Given the
observed half-lives, steady state plasma concentrations fol-
lowing a monthly dosing regimen will be well within the
afoxolaner margin of safety in dogs.
Afoxolaner increased approximately proportionally
with dose over a wide dose range of 1.0–40 mg/kg. Addi-
tionally the kinetics were unchanged upon multiple dosing.
These parameters indicate that the clearance, distribution
and absorption processes are neither saturated nor induced
after monthly dosing and the kinetics are linear.
A strong relationship between afoxolaner concentration
in plasma and efﬁcacy against ﬂeas and ticks was  deter-
mined, thus conﬁrming that afoxolaner acts systemically to
kill ﬂeas and ticks. The afoxolaner EC90 concentrations were
23 ng/mL for C. felis ﬂea and ≥100 ng/mL for R. sanguineus
sensu lato and D. variabilis ticks. Because afoxolaner is efﬁ-
cacious through most of the ﬂea and tick sampling times,
dogs had 100% efﬁcacy at most time points. The variability
was  greater at lower plasma concentrations and espe-
cially so near the points on the curve that increase steeply,
namely the slope (Gamma). The model was  nonetheless
judged to be useful because the CV of the parameters was
low, the condition number was low, and there was  a high
correlation between predicted and observed values. In clin-
ical studies, dogs administered a dose as close as possible
to the minimum therapeutic dose of 2.5 mg/kg body weight
had afoxolaner plasma concentrations above the EC90 for
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eas (C. felis), and ticks for at least one month. Efﬁcacy
tudies have conﬁrmed this result, with high levels of efﬁ-
acy reported for ﬂeas and these tick species for at least
ne month following treatment with Nexgard® oral chews
Dumont et al., 2014; Hunter et al., 2014; Mitchell et al.,
014).
. Conclusion
Afoxolaner pharmacokinetic properties have been
ested in a number of studies, and rapid absorption, high
ioavailability, moderate distribution into tissues and low
ystemic clearance were the hallmarks of this novel, soft
hewable oral formulation (Nexgard®). The prandial state
f the dog does not affect the rate or extent of absorption.
foxolaner plasma concentrations increase approximately
roportionally with the dose from 1.0 to 40.0 mg/kg. The
rug is highly bound to plasma proteins (>99% bound) in
he dog, and protein binding is independent of concen-
ration over the range of 200–10,000 ng/mL. Due to the
erminal plasma half-life of approximately 2-weeks at a
ose of 2.5 mg/kg, average afoxolaner plasma concentra-
ions were consistently above the level needed for efﬁcacy
gainst ﬂeas and ticks over one month.
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